Ginkgo Bioworks Holdings (DNA) Company Overview

Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Evolution of Ferment conference to kick off Summer 2025 BOSTON , Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquarters.

DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio.

Ginkgo Bioworks (DNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRC BOSTON , Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC), a U.S. Department of Energy-funded Bioenergy Research Center at the University of Wisconsin–Madison. This new system is designed to support the diverse needs of multiple investigators and research teams simultaneously, enabling GLBRC scientists to more efficiently discover and optimize synthesis of biofuels and bioproducts from plant biomass.

The Truveta collaboration will extend Regeneron Genetics Center's ® (RGC TM ) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers) through genetic sequencing of up to ten million additional patient volunteers, all with linked electronic health records, creating the Truveta Genome Project

Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Enzymatic DNA Synthesis Market by Service, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering. The global enzymatic DNA synthesis market is estimated to be USD 0.296 billion in 2024 and is expected to reach USD 3.90 billion by 2035, with a CAGR of 26.43% during the forecast period 2025-2035.

STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results. The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative.

- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies - STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA's synthetic DNA, Linea™ DNA, as a critical component in its manufacture.